... ENG

ESMO 2024 - Complete program listing (14 programs)

Created by oncoXchange | September 27th 2024

Dr. Tarantino - DESTINY BREAST

Q2: What are the steps you take to optimally manage ILD for patients on T-DXd (The 5 S Rules)?

Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial

ASCO 2024 - Complete program listing (16 programs)

Created by oncoXchange | June 2nd 2024

CLINICAL IMPACT Series

CLINICAL IMPACT - Ask the experts: Tumor microenvironment in breast cancer

Dr. Asselah and Dr. Park discuss the impact of microenvironment interactions on tumor growth, treatment resistance, and potential therapeutic strategies with a focus on bridging basic to clinical research.

ASCO 2024 - Abemaciclib After Progression on Prior CDK4/6 Inhibition Improved PFS in HR+/HER2- Advanced Breast Cancer

Created by oncoXchange | June 10th 2024

Dr. Tarantino - DESTINY BREAST

Q1: In which patient profiles would you consider standard of care T-DXd for in the 2L HER2+ mBC setting? And is there a patient profile you would not consider it?

Unlocking Insights: Your Questions Answered by Dr. Paolo Tarantino on 2L HER2+ Breast Cancer and the DESTINY BREAST Trial

SABCS 2023

SABCS 2023 Breast Cancer : Clinical Impact on Your Practice

Review of SABCS 2023 data in Breast Cancer with Dr. Rami Younan, Dr. Julie Lemieux & Dr. Kim Ma

ASCO 2024 - Current State of Adjuvant Therapy Strategies: Consider Subtype, Nodal Involvement, Residual Risk

Created by oncoXchange | June 17th 2024